PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ATENT & TREMEStitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/752,731

Filing Date 01/03/01

First Named Inventor Lawrence Loomis

Group Art Unit 1616

Examiner Name Dameron Levest Jones

Complete if Known

(use as many sheets as necessary)

Sheet 5 of 11 Attorney Docket Number

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
DEY.	82	KH Nasibulini et al; RU-2103991; Composition for treating streptococcal diseases - comprises purified concentrate of streptococcal bacteriophage, solution of quinsosol, dry lanolin, albumin and vegetable oil; XP-002141110			
	83	LD Demidova et al; RU2064299; Cattle mastitis therapeutic preparation - comprises lyso: amidase of specific lytic activity and mono- and di-basic sodium phosphate(s); XP-002141111	-		
		1 1	<u> </u>		
		空景	C.		
		EVI 30	里		
		ECH CENTER 1600/2000	· C		
		ONZON			
		1/20			

Examiner Signature	Plat	Date Considered	7-21-04

EXAMINER: Initial if reference of nsidered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Kn wn

Application Number 09/752,731

Filing Date 01/03/01

First Named Inventor Lawrence Loomis

Group Art Unit 1616

Examiner Name Dameron Levest Jones

Attorney Docket Number

(use as many sheets as necessary) Example 11 Attor

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Cite the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issper Examiner No.1 number(s), publisher, city and/or country where published. BABENKO et al. Enzymatic lysis of staphylococci in relation to their species and strain properties, 1990, Database Medline Online, US National Library of Medicine, Bethesda, MD, US, Database Accession No. 90297672 84 XP002170795, abstract only BARTELL, et al., Origin of polysaccharide depolymerase associated with bacteriophage infection, Journal of 85 Virology, March 1969, pp. 290-296, Vol. 3, No. 3 BEHNKE, et al., Cloning and expression in Escherichia coli, Bacillus subtilis and Streptococcus sanguis of a generator stantiviokinase - a bacterial plasminogen activator. Mol Gen Genet. December 1987, pp. 528-534, Vol. 210 86 for staphylokinase - a bacterial plasminogen activator, Mol Gen Genet, December 1987, pp. 528-534, Vol. 210 BESSEN, et al., Chemical characterization of binding properties of opacity-associated protein II from Neisserla 87 gonomheae, Infection and Immunity, January 1987, pp. 141-147, Vol. 55, No. 1 BIZIULEVICHIUS, et al., In vivo studies on lysosubtilin: 3. Efficacy for treatment of mastitis and superficial lesions of the udder and teats in cows, 1998, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, 88 US, Database Accession No. PREV199800492606, XP002183274, abstract only BOIZET, et al., Cloning, expression and sequence analysis of an endolysin-encoding gene of Lactobacillus 89 bulgaricus bacteriophage mv1, Gene, 2000, pp. 61-67, Vol. 94 CALDWELL, et al., Purification and partial characterization of the major outer membrane protein of Chlamydia 90 trachomatis, Infection and Immunity, March 1981, pp. 1161-1176, Vol. 31, No. 3 YOUNG et al. Phages will out: strategies of host cell lysis, Trends in Microbiology, Volume 8 No. 3, March 2000, 91 pp 120-127 CORBEL, et al., Soluble antigens obtained from influenza virus by treatment with non-ionic detergent, J 92 Hyg., Camb., 1970, pp. 81-96, Vol. 68 CROUX, et al., Interchange of functional domains switches enzymes specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme, Molecular Microbiology, 1993, pp.1019-25, Vol. 9, No. 5 DIAZ, et al., Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes, Proc. Natl. Acad. Sci. 94 USA, October 1990, pp. 8125-8129, Vol. 87

Examiner	Obligh	Date	7.21.04
Signature	1000	Considered	1-21-09

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 11

C mplete if Kn wn			
Application Number	09/752,731	0	
Filing Date	01/03/01	王	
First Named Inventor	Lawrence Loomis	四	
Group Art Unit	1616	=	
Examiner Name	Dameron Levest Jones	7	
Attorney Docket Number		2	

,	1	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GEV	95	DIAZ, et al., Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits, Journal of Biological Chemistry, March 25, 1991, pp. 5464-5471, Vol. 266, No. 9	
	96	DIXON, et al., Lysostaphin: an enzymatic approach to staphylococcal disease. Ill. Combined lysostaphin- methicillin therapy of established staphylococcal abcesses in mice, The Yale Journal of Biology and Medicine, August 1968, pp. 62-68, Vol. 41, No. 1	
	97	FISCHETTI, et al., Size variation of the M protein in group A streptococci, Journal of Exp. Med., June 1, 1985, pp. 1384-1401, Vol. 161, No. 6	i
	98	GARCIA, et al., Bacteriophages of Streptococcus pneumoniae: A molecular approach, Microbial Drug Resistance, Summer 1997, pp. 165-176, Vol. 3, No. 2	
	99	GARCIA, et al., Cloning, purification and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin, Journal of Virology, August 1987, pp. 2573-2580, Vol. 61, No. 8	
	100	GARCIA, et al., Modular organization of the lytic enzymes of streptococcus pneumoniae and its bacteriophages, Gene, 1990, pp. 81-88, Vol. 86	
	101	GERARDY-SCHANN, et al., Molecular cloning and functional expression of bacteriophage PK1E-encoded endoneuraminidase Endo NE, Molecular Microbiology, May 1995, pp. 441-450, Vol. 16, No. 3	
	102	GOLDBERG, et al., Studies in experimental staphylococcal endocarditis in dogs, Antimicrobial Agents and Chemotherapy, 1967, pp. 45-53	
	103	HARRISON, et al., Lysostaphin in experimental renal infections, Journal of Bacteriology, February 1967, pp. 520-524, Vol. 93, No. 2	
/	104	HARRISON, et al., Therapeutic activity of lysostaphin in experimental staphylococcal infections, Canadian Journal of Microbiology, January 1967, pp. 93-97, Vol. 13, No. 1	
V	105	HAYASHI, et al., Effects of N-Acetylmuramidase from Streptomyces rutgersensis H-46 as a food preservative, Agric. Biol. Chem., December 1989, pp. 3173-3177, Vol. 53, No. 12	

Examiner Signature Date Considered 7-21-0	74
---	----

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

stitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 11 Sheet 8

_					
		Complete if Known			
	Application Number	09/752,731		4	
ĺ	Filing Date	01/03/01	न्न	M	
	First Named Inventor	Lawrence Loomis	<i>S</i> .	6 'Ca	
	Group Art Unit	1616	C		,
	Examiner Name	Dameron Levest Jones	7	0 2	え
	Attorney Docket Number		3	1 2 1	S
				6	
١	I PATENT LITERATURE I	DOCUMENTS		03	
		rticle (when appropriate), title of	T²	30	

		OTHER BRICK ART. MON RATENT LITERATURE DOCUMENTS	
	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
40	106	HAYASHIDA, et al., Further characterization of PL-1 phage associated N-acetylmuramidase of Lactobacillus casei, Journal of General Microbiology, May 1987, pp. 1343-1349, Vol. 133, No. 5	
	107	HIGUCHI, et al., Transfection of streptococcus sanguis by phage deoxynbonucleic acid isolated from streptococcus mutans, Infection and Immunity, March 1977, pp. 945-949, Vol. 15, part 3	
	108	HUAN, et al., Methicillin-resistant staphylococcus aureus infection and its treatment in burned patients, Chinese Journal of Surgery, 1994, Vol. 32, No. 4, abstract	
	109	HUGHEY, et al., Antimicrobial activity of lysozome against bacteria involved in food spoilage and food-borne disease, Applied and Environmental Microbiology, September 1987, pp. 2165-2170, Vol. 53, No. 9	
	110	KOHLER, Systemic therapy with aerosols Aerosols in Medicine: Principles, Diagnosis and Therapy, 1993, Elseveir Science Publishers, pp. 303-319	
	111	LAWMAN, et al., Molecular cloning of the extracellular endodextranase of streptococcus salivarius, Journal of Bacteriology, December 1991, pp. 7423-7428, Vol. 173, No. 23	
	112	LOESSNER, et al., Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of staphylococcus aureus bacteriophage 187, Journal of Bacteriology, August 1999, pp. 4452-4460, Vol. 181, No. 15	
	113	LOESSNER, et al., Modified listeria bacteriophage lysin genes (ply) allow efficient overexpression and one - step purification of biochemically active fusion proteins, Applied and Environmental Microbiology, August 1996, pp. 3057-3060, Vol. 62, No. 8	
-	114	LOPEZ, et al., Architecture and domain interchange of the pneumococcal cell wall lytic enzymes, Genetics of Streptococci, Enterococci and Lactococci, Developments in Biological Standardization, 1995, pp. 273-281, Vol. 85	
	115	LOPEZ, et al., The pneumococcal cell wall degrading enzymes a modular design to create new lysins, Microbial Drug Resistance, November 2, 1997, pp. 199-211, Vol. 3, No. 2	
V	116	MARTIN, et al., Functional analysis of the two-gene lysis system of the pnemococcal phage Cp-1 in homologous and heterologous host cells, Journal of Bacteriology, January 1998, pp. 210-217, Vol. 180, No. 2	-

Examiner Signature	De 1000	Date 7-21-04	/

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Sheet

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

T & Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 11

Complete if Known			
Application Number	09/752,731	四	
Filing Date	01/03/01	一	
First Named Inventor	Lawrence Loomis	_ 유	
Group Art Unit	1616	3	
Examiner Name	Dameron Levest Jones	平	
Attorney Docket Number		1	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
REV	117	MUKHLIS, et al., Characterization and Immunogenicity of HSV-1 antigens obtained following zwitteronic detergent treatment; Vaccine, September 1986, pp. 191-196, Vol. 4	
	118	NELSON, et al., Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme, PNAS, March 27, 2001, pp. 4107-4112, Vol. 98, No. 7	
	119	NELSON, et al., Selective and rapid killing of group A streptococci using a muralytic enzyme, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US and abstracts of the General Meeting of the American Society for Microbiology, 2000, pp. 32-33	
	120	OKI, et al., Functional and structural features of the holin HOL protein of the Lactobacillus plantarum phage analysis in escherichia coli system, Gene, 1997, pp. 137-145, Vol. 197	
	121	OKUHARA, et al., Preparation of group A streptococcal cell membranes by treatment with group C streptococcus phage - associated lysin, Annales Paediatrici Japonici, June 1983, pp. 10-19, Vol. 29, No. 2	
	122	PATTON, et al., Routes of delivery: case studies, Pulmonary delivery of peptides and proteins for systemic action, Advanced Drug Delivery Reviews, 1992, pp. 179-196, Vol. 8	
	123	POLAK, et al., In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant staphylococcus aureus, Diagn. Microbiol. Infect. Dis., 1993, pp. 265-270, Vol. 17	
-	124	RAINA, Purification of streptococcus group C bacteriophage lysin, Journal of Bacteriology, January 1981, pp. 661-663, Vol. 145, No. 1	
	125	RONDA, et al., Infection of streptococcus oralis NCTC 11427 by pneomococcal phages, FEMS Microbiology Letters, 1989, pp. 187-192, Vol. 65	
	126	SANZ, et al., Construction of a multifunctional pneumococcal murein hydrolase by module assembly, Eur. J. Biochem., February 1, 1996, pp. 601-605, Vol. 235, No. 3	
$\overline{\mathbf{V}}$	127	SATO, et al., Partial characterization of n - Butanot - solubilized rejection - type antigens of syngeneic murine colon tumors, JNCI, April 1985, Vol. 74, No. 4	***

		1		
Examiner Signature	(PO)	lato	Date Considered	7-21-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number 09/752,731 TIPE PRINT Name Dameron Levest Jones

Complete if Known

09/752,731 TIPE PRINT Name Dameron Levest Jones

Attorney Docket Number

(use as many sheets as necessary)

Sheet 10 of 11

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	E
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Ker	128	SHEEHAN, et al., Analysis of the catylytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling; FEMS Microbiology Letters, 1996, pp. 23-28, Vol. 140	
	129	SHEEHAN, et al., The lytic enzyme of the pneumococcal phage Dp-1: A chimeric lysin of intergeneric origin, Molecular Microbiology, 1997, pp. 717-725	
	130	WITTE, et al., Characterization of escherichia coli lysis using a family of chimeric E-L genes, FEMS Microbiology Letters, 1998, pp. 159-167, Vol. 164	
1/	131	YARNALL, et al., Isolation and partial characterization of a type II Fc receptor from a group A streptococcus, Molecular and Cellular Biochemistry, 1986, pp. 57-66, Vol. 70	
V	132	CISANI, et al., High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme, Antimicrobial Agents and Chemotherapy, April 1982, pp. 531-535, Vol.21, No. 4	

Examiner Signature Date Considered 7-21-04			····	_
	Examiner	1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons an

Substitute for form 1449A/PTO

PATENT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

I Total Control of the Control of th	of intolimation unless it contains a valid Oiv	D CONTROL TO
	C mplete if Known	
Application Number	09/752,731	
Filing Date	01/03/01	4
First Named Inventor	Lawrence Loomis	THE T
Group Art Unit	1616	至 3
Examiner Name	Dameron Levest Jones	3
Attorney Docket Number		1/2/

21				_		Applica	ation Number	09/75	52,731
SINFO	RMA	TION D	DIS	CLOSU	IRE	Filing (Date	01/03	3/01
STA	TEME	NT BY	Α	PPLICA	NT	First N	amed Inventor	Lawr	ence Loomis
						Group	Art Unit	1616	23
	(use as i	many sheet	s as	necessary)		Exami	ner Name	Dame	eron Levest Jones
Sheet	1		of	11		Attorne	ev Docket Number	-	2.
	·						,, = 0.0		
	-				U.S. PA	TENT D	OCUMENTS		eron Levest Jones
	Ĭ	Docu	ment	Number			Name of Patentee or Appl	icant of	Γ
Examiner Initials *	Cite No. ¹	Number - Kir	nd Co	de ² (if known)	Publication MM-DD-		Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	UE-60569	54		05/02	/00	Fischetti, et el.		
	2	US- 59978	62		12/07	/99	Fischetti, et al.		
	3	US- 59852	71		11/16	/99	Fischetti, et al.		
	4	US- 56885	01		11/18	/97	Memil, et al.		
	1	US- 47429	81		05/10	/88	Converse		
	6	US- 20197		Δ	11/05	11/05/35 Mahanna	Mahannah		
	7	DS- 27639		<u> </u>	09/25	/56	McMillan		
	8	US- 54797		_	01/02		Burtch, et al.		
	9	US- 34654	_	<u> </u>	09/09		Fisher		
	10	US- 23152			03/30		Lancaster		
	11	US- 560410		10	02/18		Fischetti, et al.		
	12	US- 52602			11/09		Robinson, et al.		
	13	US- 49576			09/18		Norris		
	14	US- 60175	-		01725		Fischetti, et al.		
	15 16	US- 61329			10/17		Stemmer		
	16	US- 385242 US- 626494			12/08		Gaeumann, et al.		-
	18	US- 625486	-		07/24		Fischetti, et al.		
	18	US- 624832			08/19/		Pischetti, et al.		
	20	US- 623866			05/25	_	Fischetti, et al.		
	20	U3- 023800	,,		05/29/	سران	Fischetti, et al.		

		FOREIGN PA	TENT DOCK	MENTS		
Eveniess	0:44	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	To
	21	EP-0510907 A 2	10/28/92	Agricultural & Food Bes.		
	22	WO-9702351	01/23/97	CIBA Gelgy AG, et al.	2	
	23	WO-9607329	03/14/96	Univ. Maryland		
	24	WO-9904809	02/04/99	Ambi, Inc.		
	25	FR-2357246	02/03/78	Martinez		
	26	· WO-9531562	11/23/95	Quest Inernational B.V.	_	
	27	EP-587541 A1	03/16/94	Tecnogen ScpA		

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known						
Application Number	09/752,731					
Filing Date	01/03/01					
First Named Inventor	Lawrence Loomis					
Group Art Unit	1616					
Examiner Name	Dameron Levest Jones					
Attorney Docket Number	·					

			U.S. PATENT D	OCUMENTS	
Examiner Initials *	Cite No.'	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
	28	US- 6056955	05/02/00	Fischotti, et al.	Figures Appear
$\overline{}$	29	US- 5882631	03/16/99	Suga, et al.	
$\overline{}$	30	US- 5741487	04/21/98	Asai, et at.	
	31	US- 6113887	09/05/00	Mori, et al.	
	82	US- 4122158	10/24/78	Schmitt	加加
	33	US- 3983209	09/28/76	Schmitt	2 % C
	34	NS- 4885163	12/05/89	Shaar, et al.	
	35	US-8177554	01/23/01	Woo, et al.	EN TO
	36	US- 6187757	02/13/01	Clackson, et al.	40
	37	US- 5162226	11/10/92	Beachey, et al.	73 73
	38	US- 6335012	01/01/02	Fischetti, et al.	
	39	US- 6326002	712/04/01	Fischetti, et al.	600
	40	US- 6277399	08/21/01	Fischetti, et al.	8
	41	US- 4062941	12/13/17	Davies	9
	42	US- 5571667	11/05/68	Chu, et al.	
	43	US- 5514602	05/07/96	Brooks Jr, et al.	
	44	US- 5500350	03/19/96	Baker, et al.	
	45	US- 5384265	01/24/95	Kidwell, et al.	
	46	US- 4361537	11/30/82	Deutsch, et al.	
	47	US- 5120643	6/09/92	Chingret at.	

		FOREIGN-PA	TENT DOCU	IMÈNTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
	48	WO-9323544	11/25/93	The University Court of the University of Glasgew	Tigures Appear	<u> </u>
	49	EP-0293249 A1	11/30/88	Arrad Corporation Limited		
	50	EP-0646646 A2	04/05/95	Bristol-Myers Squibb Company		
	51	FP-0359873 A1	03/28/90	The Public Health Research Inst of the City of New York		
				New York		

Examiner Signature Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449A/PTO

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 11

Complete if Known					
Application Number	09/752,731				
Filing Date	01/03/01				
First Named Inventor	Lawrence Loomis				
Group Art Unit	1616				
Examiner Name	Dameron Levest Jones				
Attomey Docket Number					

			U.S. PATENT D	OCUMENTS	
Examiner Initials *	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	- 52	US 4048728	- 08/14/90	Longoria	
	53	US- 4459361	07/10/84	Gefter	
	-54	US- 45528397	11/12/85	Gould, et al.	
	55	US- 4313734	02/02/82	Leuvering	HCG !
	56	US-4847189	07/11/89	Snyder, et al.	
	57	US- 4497900	/ 02/05/85	Abram, et al.	CENTER CENTER
	58	US- 4707543	3/11J187	Zollinger, et al.	
	59	US- 5763251	5763251 09/09/96		四四
	60	US- 6159688	12/12/00	Borchert, et al.	
	61	US- 4784948	41,15/88	Scott, et al.	
	62	US- 5760026	06/03/98	Blackburn, et al.	S
	63	US- 5602040	02/11/97 7	May, grat.	
	64	US- 4521252	06/04/85	Miyake et al.	
	65	US- 4355022	10/19/82	Rabussay	
	66	US- 4115546	09/19/78	Vidra, et al	
	67	US- 4116327	09/26/78	Eglifton, et et.	
	68	US- 3929994	12/30/75	Hirsch, et al.	
	69	US- 6083684	07/04/00	Gasson	
	70	US- 5360617	11/01/94	Gasson	
	71	US-5070174	01/07/92	Buck et al	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant		
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Document	Passages or Relevant Figures Appear	T°	
				``			
						····-	
					<u> </u>		

Examiner Signature Date Considered 7-21-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE presport in a collection of information unless than 10 presport in a collection of information unless than 10 presport in a collection of information unless than 10 presport in a collection of information unless than 10 presport in a collection of information unless than 10 presport in a collection of information unless than 10 presport in a collection of information unless than 10 present in the 10 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known					
Application Number	09/752,731				
Filing Date	01/03/01				
First Named Inventor	Lawrence Loomis				
Group Art Unit	1616				
Examiner Name	Dameron Levest Jones				
Attorney Docket Number					

			U.S. PATENT D	OCUMENTS		
Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials *		No. ¹ Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear	i
	72	US-5604110	02/18/97	Baker, et al.		
	73	US-5294369 -///	03/15/94	Shigekawa, et al.		
	74	US-5372931	12/13/94	Friedman, et al.		
	75	US-4933185	6612190	X / Wheatley, et al.		\
	76	US- 5108758	04/28/92	O Allywood, et al.	一点 4	'n
	77	US- 4713249	(12)15/87	Schroder	C Z	Ò
	78	US- 4812445	03/14/89	Eden, et al.	~ P	え
	79	US- 3622677	11/23/71	Short epal.	mí o	\ <u>'</u>
	80	US-4369308	01/18/83	Trubiano	20	7
	-81	US-6393658	-02/28/95	Olsen		-
		US-			2 3	
		US-			<u> </u>	
	7.6	US-				
	I	US-			<u> </u>	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

		FOREIGN PA	TENT DOCU	MENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	-
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
						
	 					

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subştitute for form 1449A/PTO

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	(,
Shoot	11	 f	11

Complete if Known						
Application Number	09/752,731	-1				
Filing Date	January 3, 2001	77				
First Named Inventor	Lawrence Loomis	工				
Group Art Unit	1616	元				
Examiner Name	Jones, Dameron Levest	3				
Attorney Docket Number		3				

			U.S. PATENT D	OCUMENTS	
Examiner Initials *	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	133	US 5605793	02/25/97	Stemmer	
$\overline{}$	134	US- 6355477	03/12/02	Fischetti et al	
	135	US- 6331405	12/18/01	Rambukkana et al	
-	136	US- 6190659	02/20/01	Pancholi et al	
	137	US- 5985654	11/16/99	Fischetti et al	
	138	US- 5842314	1/24/98	Scott et al	:
	139	US- 5910441	/06/08/99	Rocha et al	
	140	US- 5786205	07/28/88	Fischetti et al	:
	141	US-5976792	11/02/99	Cheung et al	
	142	US- 5821088	10/13/98	(Darzins et al	1
	143	US- 5723303	93/03/98	elschefti et al	
	144	US- 5643767	07/01/97/	Fischetti et al	ä
·	145	US- 5707822	01/13/98	Fischetti et al	
	146	US- 5616686	04/01/97	Fischetti et al	
	147	US- 5604109	02/18/97	Fischetti et al	
	148	US- 5587288	12/24/96	Cheung et al	
	149	US- 5556944	09/17/96	Fischetti et al	
	150	US- 5352588	10/04/94	Fischetti et al	
_	151	US- 5968763	10/19/99	Fischetti et al	
	162	US-4784948	11/15/88	Scott et al	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document			
		·					
-							

	$\perp \triangle$			
Examiner Signature	TO	Klado	Date Considered	7-21-04

EXAMINER: Initial if relevence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.